Published in QJM on September 01, 1996
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations | NCT00302146
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol (2009) 2.79
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab (2007) 2.21
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol (2012) 2.20
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol (2008) 1.87
The link between the GBA gene and parkinsonism. Lancet Neurol (2012) 1.80
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord (2014) 1.76
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain (2015) 1.71
Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med (2011) 1.71
The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis (2010) 1.65
The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord (2013) 1.63
The function of α-synuclein. Neuron (2013) 1.63
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem (2011) 1.42
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol (2014) 1.37
Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord (2010) 1.31
The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep (2010) 1.28
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis (2010) 1.21
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics (2009) 1.14
Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther (2012) 1.10
The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord (2009) 1.10
Sphingolipid lysosomal storage disorders. Nature (2014) 1.08
Gaucher disease and the synucleinopathies. J Biomed Biotechnol (2006) 1.03
α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A (2016) 0.97
Genetics of neurodegenerative diseases: insights from high-throughput resequencing. Hum Mol Genet (2010) 0.96
Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med (2012) 0.96
Gaucher disease: insights from a rare Mendelian disorder. Discov Med (2012) 0.95
'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis (2008) 0.95
Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet (2014) 0.94
Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J Neurochem (2012) 0.94
Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog (2013) 0.93
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy (2015) 0.92
Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS One (2013) 0.91
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
Greater risk of parkinsonism associated with non-N370S GBA1 mutations. J Inherit Metab Dis (2012) 0.91
Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration. Br J Pharmacol (2014) 0.90
Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. Appl Clin Genet (2011) 0.90
Parkinsonism associated with glucocerebrosidase mutation. J Clin Neurol (2011) 0.89
Genetic susceptibility in Parkinson's disease. Biochim Biophys Acta (2008) 0.89
Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis (2014) 0.87
Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes. J Inherit Metab Dis (2012) 0.86
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. Hum Mol Genet (2014) 0.85
The association between ß-glucocerebrosidase mutations and parkinsonism. Curr Neurol Neurosci Rep (2013) 0.85
Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain (2014) 0.85
Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. Front Neurol (2012) 0.85
Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J Inherit Metab Dis (2014) 0.85
Recent advances in Parkinson’s disease genetics. J Neurol (2014) 0.84
Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis (2014) 0.83
A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Dis Model Mech (2013) 0.83
Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxid Redox Signal (2015) 0.81
Pathological looping in the synucleinopathies: investigating the link between Parkinson's disease and Gaucher disease. Dis Model Mech (2011) 0.81
Development of targeted therapies for Parkinson's disease and related synucleinopathies. J Lipid Res (2014) 0.80
Parkinsonism in type 1 Gaucher's disease. J Neurol Neurosurg Psychiatry (2006) 0.80
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci Rep (2016) 0.80
The significance of GBA for Parkinson's disease. J Inherit Metab Dis (2014) 0.80
The expanding role of genetics in the lewy body diseases: the glucocerebrosidase gene. Arch Neurol (2009) 0.79
Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis (2016) 0.79
A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease. JIMD Rep (2011) 0.78
Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. J Neurol (2013) 0.78
Astrocytes and lysosomal storage diseases. Neuroscience (2015) 0.78
Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol Dis (2015) 0.78
Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. Mol Neurobiol (2016) 0.77
Gaucher disease plus. J Med Genet (1997) 0.76
Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurol Genet (2016) 0.76
The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron (2017) 0.75
Adult Gaucher disease in southern Tunisia: report of three cases. Diagn Pathol (2012) 0.75
Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings. J Genet Couns (2017) 0.75
Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience. J Inherit Metab Dis (2013) 0.75
Arylsulphatase A activity in familial parkinsonism: a pathogenetic role? J Neurol (2014) 0.75
Glucocerebrosidase and parkinsonism: lessons to learn. J Neurol (2016) 0.75
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet (2000) 4.27
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology (2008) 3.83
Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet (1995) 3.35
Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol (2000) 2.90
The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med (2000) 2.63
Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet (1998) 2.37
How B12 deficiency can impact on the individual and how society can impact on B12 deficiency. Isr Med Assoc J (2001) 2.36
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab (2003) 2.29
Exercise-induced bronchial lability in children with a history of wheezy bronchitis. Arch Dis Child (1972) 2.23
Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol (2003) 2.17
Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med (1994) 2.13
Mutations in Jewish patients with Gaucher disease. Blood (1992) 1.95
Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res (2003) 1.88
Gait instability and fractal dynamics of older adults with a "cautious" gait: why do certain older adults walk fearfully? Gait Posture (2005) 1.77
Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab (2009) 1.72
Bilateral coordination of gait and Parkinson's disease: the effects of dual tasking. J Neurol Neurosurg Psychiatry (2009) 1.70
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology (2007) 1.70
Lung involvement and enzyme replacement therapy in Gaucher's disease. QJM (2001) 1.70
Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord (1997) 1.69
Superficial hemosiderosis of the central nervous system. Mov Disord (1994) 1.66
Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J Neurol (2005) 1.63
Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis (2008) 1.63
Plasma chitotriosidase activity in patients with beta-thalassemia. Am J Hematol (2002) 1.55
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis (2003) 1.52
Lead poisoning in a West Bank Arab Village. Arch Intern Med (1984) 1.49
Esophageal involvement in chronic granulomatous disease. Case report and review. Pediatr Radiol (1995) 1.48
Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet (1984) 1.46
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis (2004) 1.45
Multiple myeloma in the geriatric patient. Cancer (1990) 1.44
High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol (2001) 1.43
Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet (1995) 1.42
Treatment of patients with Niemann-Pick type is using repeated amniotic epithelial cells implantation: correction of aggregation and coagulation abnormalities. Clin Pediatr (Phila) (1997) 1.42
Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry (2000) 1.42
Quantitative anal sphincter EMG in multisystem atrophy and 100 controls. J Neurol Neurosurg Psychiatry (2001) 1.42
Halothane modifies ischemia-associated injury to the voltage-sensitive calcium channels in canine heart sarcolemma. Anesthesiology (1994) 1.41
Feto-feto-fetal transfusion syndrome in monozygotic monochorionic triamniotic triplets: vascular evaluation by a cast model. Placenta (2005) 1.40
Skeletal manifestations in Gaucher disease: presentation and treatment. Isr Med Assoc J (1999) 1.40
Skeletal aspects of Gaucher disease: a review. Br J Radiol (2002) 1.39
Neurocognitive testing in late-onset Tay-Sachs disease: a pilot study. J Inherit Metab Dis (2008) 1.39
Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher's disease. Postgrad Med J (2002) 1.39
Post-traumatic meningococcemia in a patient with deficiency of the C7 complement component. Isr J Med Sci (1990) 1.39
Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience. Isr J Med Sci (1995) 1.38
Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol Genet Metab (2009) 1.34
Cytokines in Gaucher's disease. Eur Cytokine Netw (1999) 1.32
Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost (1978) 1.30
An instrumented timed up and go: the added value of an accelerometer for identifying fall risk in idiopathic fallers. Physiol Meas (2011) 1.26
Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis (2009) 1.26
The effect of atmospheric ions on the respiratory system of infants. Pediatrics (1966) 1.22
An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci (1995) 1.20
Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia. J Clin Neurosci (2003) 1.20
Mutations causing Gaucher disease. Hum Mutat (1994) 1.20
Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat (2006) 1.18
Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis (2001) 1.17
Quality of life and survival following intensive medical care. Q J Med (1989) 1.14
Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord (2001) 1.13
Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol (2011) 1.11
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis (2001) 1.11
Gaucher's disease. Lancet (2001) 1.09
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol (2004) 1.09
Treadmill training for the treatment of gait disturbances in people with Parkinson's disease: a mini-review. J Neural Transm (Vienna) (2008) 1.09
Subjective memory complaints in elders: depression, anxiety, or cognitive decline? Acta Neurol Scand (2012) 1.08
Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br J Haematol (1999) 1.08
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics (2009) 1.05
Inappropriate antidiuretic hormone secretion in an infant with severe pneumonia. Am J Dis Child (1975) 1.03
Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence. J Struct Biol (2008) 1.02
Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan. Ann Neurol (1978) 1.02
Hand rhythmic tapping and timing in Parkinson's disease. Parkinsonism Relat Disord (2004) 1.02
Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res (1996) 1.01
Neuronopathic forms of Gaucher's disease. Baillieres Clin Haematol (1997) 1.00
Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology (2001) 1.00
Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther (1983) 0.99
Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in-frame start codon. Hum Mutat (2004) 0.99
Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet (1993) 0.99
Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements. J Ultrasound Med (1997) 0.99